TargoPep works in collaboration with pharmaceutical R&D to design, research and refine targeted delivery solutions for gene therapy treatments.
Our biological and chemical expertise, patented chemical solutions and innovative design principles enable our bespoke, peptide-based delivery systems to provide targeted drug delivery for your asset. Our technology overcomes barriers often associated with the clinical application of gene-based therapeutics.
Current solutions to the poor delivery of gene therapies rely on non-ideal and clinically limiting methods, which are expensive and time-consuming to adapt.
Our modular, dynamic and versatile approach enables TargoPep to address these delivery needs and expand the possibilities for, and potential of, gene therapies in the clinic.
Current solutions to the poor delivery of gene therapies rely on non-ideal and clinically limiting methods, which are expensive and time-consuming to adapt.
Our modular, dynamic and versatile approach enables TargoPep to address these delivery needs and expand the possibilities for, and potential of, gene therapies in the clinic.
TargoPep works in collaboration with your research team, to develop a bespoke solution that fully addresses your drug delivery needs.
Providing delivery expertise, chemical solutions and assay development, the assets developed in collaboration with TargoPep maximise probability of success in the clinic.
Augmenting your therapeutic pipeline with TargoPep’s unique delivery technologies accelerates those therapies towards the clinic and their markets.
TargoPep’s modularity and diversity of solutions provides for our clients, viable alternatives to other delivery options.
TargoPep Ltd., Suite 2, Orchard Brae House, 30 Queensferry Road, Edinburgh EH4 2HS, United Kingdom
info@targopep.com
TargoPep Ltd. is a company registered in Scotland SC715354 | All content © 2024 TargoPep Ltd.